Skip to main content
John M. Inadomi

John M. Inadomi, MD

Languages spoken: English
  • Dr. John Inadomi received an undergraduate degree in mechanical engineering from M.I.T. and an M.D. from the University of California, San Francisco (UCSF), where he completed his residency in internal medicine and fellowship in gastroenterology. He has been on the faculty of the University of New Mexico, the University of Michigan, UCSF, and the University of Washington where he served as the Division Head of Gastroenterology for 10 years. In 2020, Dr. Inadomi joined the University of Utah Health as the Jon M. Huntsman Presidential Chair and the Chair of the Department of Internal Medicine.

    Dr. Inadomi is a gastroenterologist with expertise in comparative effectiveness research. He has received funding from the National Institutes of Health (NIH) to evaluate new techniques to decrease mortality from esophageal adenocarcinoma, and to test novel interventions to increase adherence to colorectal cancer screening tests. He is an associate editor of Gastroenterology and is currently the President-Elect of the American Gastroenterological Association (AGA), and will become the President of the AGA in 2021.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Gastroenterology)
  • Dr. John Inadomi received an undergraduate degree in mechanical engineering from M.I.T. and an M.D. from the University of California, San Francisco (UCSF), where he completed his residency in internal medicine and fellowship in gastroenterology. He has been on the faculty of the University of New Mexico, the University of Michigan, UCSF, and the University of Washington where he served as the Division Head of Gastroenterology for 10 years. In 2020, Dr. Inadomi joined the University of Utah Health as the Jon M. Huntsman Presidential Chair and the Chair of the Department of Internal Medicine.

    Dr. Inadomi is a gastroenterologist with expertise in comparative effectiveness research. He has received funding from the National Institutes of Health (NIH) to evaluate new techniques to decrease mortality from esophageal adenocarcinoma, and to test novel interventions to increase adherence to colorectal cancer screening tests. He is an associate editor of Gastroenterology and is currently the President-Elect of the American Gastroenterological Association (AGA), and will become the President of the AGA in 2021.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Gastroenterology)

    Education history

    Fellowship Gastroenterology - University of California, San Francisco Fellow
    Internal Medicine - University of California, San Francisco Resident
    Internship Internal Medicine - University of California, San Francisco Intern
    Medicine - University of California, San Francisco M.D.
    Undergraduate Mechanical Engineering - Massachusetts Institute of Technology S.B.

    Selected Publications

    Journal Article

    1. Croswell JM, Corley DA, Lafata JE, Haas JS, Inadomi JM, Kamineni A, Ritzwoller DP, Vachani A, Zheng Y, National Cancer Institute Population-based Research to Optimize the Screening Process PROSPR II Consortium (2021). Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Prev Med, 151, 106595. (Read full article)
    2. Issaka RB, Bell-Brown A, Snyder C, Atkins DL, Chew L, Weiner BJ, Strate L, Inadomi JM, Ramsey SD (2021). Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. JAMA Netw Open, 4(8), e2120159. (Read full article)
    3. Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I (2021). The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 161(2), 487-494.e4. (Read full article)
    4. Ozanne EM, Silver ER, Saini SD, Rubenstein JH, Lansdorp-Vogelaar I, Bowers N, Tan SX, Inadomi JM, Hur C (2021). Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. Am J Gastroenterol, 116(8), 1730-1733. (Read full article)
    5. Sultan S, Siddique SM, Singh S, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Kaul V, Lim JK, Mustafa RA, Falck-Ytter Y, Inadomi JM, American Gastroenterological Association (2021). AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. Gastroenterology. (Read full article)
    6. Issaka RB, Taylor P, Baxi A, Inadomi JM, Ramsey SD, Roth J (2021). Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. JAMA Netw Open, 4(4), e216454. (Read full article)
    7. Rubenstein JH, Inadomi JM (2020). Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am, 31(1), 77-90. (Read full article)
    8. Curtius K, Rubenstein JH, Chak A, Inadomi JM (2020). Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas. Gut. (Read full article)
    9. Sultan S, Siddique SM, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Francis D, Inadomi JM, Lim JK, Falck-Ytter Y, Mustafa RA, American Gastroenterological Association Electronic address ewilsongastroorg (2020). AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology, 159(5), 1935-1948.e5. (Read full article)
    10. Issaka RB, Li L, Fedorenko C, Ko CW, Inadomi JM, Ramsey SD (2020). Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. J Racial Ethn Health Disparities, 7(5), 967-974. (Read full article)
    11. Issaka RB, Akinsoto NO, Strait E, Chaudhari V, Flum DR, Inadomi JM (2020). Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. Therap Adv Gastroenterol, 13, 1756284820945388. (Read full article)
    12. Snider EJ, Kaz AM, Inadomi JM, Grady WM (2020). Chemoprevention of esophageal adenocarcinoma. Gastroenterol Rep (Oxf), 8(4), 253-260. (Read full article)
    13. Rubenstein JH, Tavakkoli A, Koeppe E, Ulintz P, Inadomi JM, Morgenstern H, Appelman H, Scheiman JM, Schoenfeld P, Metko V, Stoffel EM (2020). Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants. Clin Transl Gastroenterol, 11(4), e00151. (Read full article)
    14. Inadomi JM, Issaka RB, Green BB (2019). What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%? Clin Gastroenterol Hepatol. (Read full article)
    15. Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi J (2019). Optimizing Management of Patients with Barrett's Esophagus and Low-grade or No Dysplasia Based On Comparative Modeling: Optimizing Barrett's esophagus management. Clin Gastroenterol Hepatol. (Read full article)
    16. Burnett-Hartman AN, Kamineni A, Corley DA, Singal AG, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng Y (2019). Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. EGEMS (Wash DC), 7(1), 37. (Read full article)
    17. Rastogi N, Xia Y, Inadomi JM, Kwon SC, Trinh-Shevrin C, Liang PS (2019). Disparities in colorectal cancer screening in New York City: An analysis of the 2014 NYC Community Health Survey. Cancer Med, 8(5), 2572-2579. (Read full article)
    18. Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM (2018). Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Res, 79(3), 495-504. (Read full article)
    19. Issaka RB, Inadomi JM (2018). Low-Value Colorectal Cancer Screening: Too Much of a Good Thing? JAMA Netw Open, 1(8), e185445. (Read full article)
    20. Inadomi JM, Saxena N (2018). Endoscopic surveillance or ablation for Barrett's esophagus? Transl Gastroenterol Hepatol, 3, 102. (Read full article)
    21. Inadomi J, Alastal H, Bonavina L, Gross S, Hunt RH, Mashimo H, di Pietro M, Rhee H, Shah M, Tolone S, Wang DH, Xie SH (2018). Recent advances in Barrett's esophagus. Ann N Y Acad Sci, 1434(1), 227-238. (Read full article)
    22. Inadomi JM, Saxena N (2018). Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective? Dig Dis Sci, 63(8), 2094-2104. (Read full article)
    23. Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, Chak A, Iyer PG (2018). The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology, 154(8), 2068-2086.e5. (Read full article)
    24. Choi AY, Strate LL, Fix MC, Schmidt RA, Ende AR, Yeh MM, Inadomi JM, Hwang JH (2017). Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointest Endosc, 87(4), 1023-1028. (Read full article)
    25. Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C (2017). Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol, 16(3), 392-400.e7. (Read full article)
    26. Ende AR, De Groen P, Balmadrid BL, Hwang JH, Inadomi J, Wojtera T, Egorov V, Sarvazyan N, Korman L (2017). Objective Differences in Colonoscopy Technique Between Trainee and Expert Endoscopists Using the Colonoscopy Force Monitor. Dig Dis Sci, 63(1), 46-52. (Read full article)
    27. Rubenstein JH, Pohl H, Adams MA, Kerr E, Holleman R, Vijan S, Dominitz JA, Inadomi JM, Provenzale D, Francis J, Saini SD (2017). Overuse of Repeat Upper Endoscopy in the Veterans Health Administration: A Retrospective Analysis. Am J Gastroenterol, 112(11), 1678-1685. (Read full article)
    28. Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C (2017). Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clin Gastroenterol Hepatol, 15(9), 1471-1474. (Read full article)
    29. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C (2017). Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol, 15(9), 1397-1404.e7. (Read full article)
    30. Ritvo P, Myers RE, Serenity M, Gupta S, Inadomi JM, Green BB, Jerant A, Tinmouth J, Paszat L, Pirbaglou M, Rabeneck L (2016). Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Prev Med, 101, 229-234. (Read full article)
    31. Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C (2017). The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol, 112(8), 1256-1264. (Read full article)
    32. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S (2017). Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol, 112(7), 1032-1048. (Read full article)
    33. Saxena N, Inadomi JM (2017). Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. Gastrointest Endosc Clin N Am, 27(3), 397-421. (Read full article)
    34. Johnson DA, Lieberman D, Inadomi JM, Ladabaum U, Becker RC, Gross SA, Hood KL, Kushins S, Pochapin M, Robertson DJ (2016). Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clin Gastroenterol Hepatol, 15(6), 883-891.e9. (Read full article)
    35. ASGE Endoscopy Unit Quality Indicator Taskforce, Day LW, Cohen J, Greenwald D, Petersen BT, Schlossberg NS, Vicari JJ, Calderwood AH, Chapman FJ, Cohen LB, Eisen G, Gerstenberger PD, Hambrick RD 3rd, Inadomi JM, MacIntosh D, Sewell JL, Valori R (2017). Quality indicators for gastrointestinal endoscopy units. VideoGIE, 2(6), 119-140. (Read full article)
    36. Inadomi JM (2016). Editorial: Endoscopic Sedation: Who, Which, When? Am J Gastroenterol, 112(2), 303-305. (Read full article)
    37. Inadomi JM (2017). Screening for Colorectal Neoplasia. N Engl J Med, 376(2), 149-156. (Read full article)
    38. Ko LK, Taylor VM, Yoon J, Copeland WK, Hwang JH, Lee EJ, Inadomi J (2016). The impact of medical tourism on colorectal screening among Korean Americans: A community-based cross-sectional study. BMC Cancer, 16(1), 931. (Read full article)
    39. Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM, Wender RC (2016). Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review. JAMA, 316(20), 2135-2145. (Read full article)
    40. Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA, PROSPR Consortium (2016). Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med, 51(4), e107-15. (Read full article)
    41. Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, Ogura Y, Matsuzaki J, Iwasaki E, Hosoe N, Masaoka T, Inadomi JM, Suzuki H, Kanai T, Namiki S (2016). A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. Dig Liver Dis, 48(10), 1180-6. (Read full article)
    42. Katzka DA, Friedman LS, Inadomi JM, Kalloo AM, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR (2016). Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 151(1), 45. (Read full article)
    43. Wernli KJ, Brenner AT, Rutter CM, Inadomi JM (2015). Risks Associated With Anesthesia Services During Colonoscopy. Gastroenterology, 150(4), 888-94; quiz e18. (Read full article)
    44. Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, Thomas JP, Vijan S, Inadomi JM (2015). Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. Am J Gastroenterol, 111(1), 105-14. (Read full article)
    45. Brenner AT, Gupta S, Ko LK, Janz N, Inadomi JM (2016). Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations. J Health Care Poor Underserved, 27(2), 465-78. (Read full article)
    46. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K (2015). Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology, 149(6), 1599-606. (Read full article)
    47. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M (2015). An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 149(3), 577-85.e4; quiz e14-5. (Read full article)
    48. Shergill AK, Conners EE, McQuaid KR, Epstein S, Ryan JC, Shah JN, Inadomi J, Somsouk M (2015). Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer. Gastrointest Endosc, 82(3), 529-37.e1. (Read full article)
    49. Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M (2014). The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Med Decis Making, 35(6), 726-33. (Read full article)
    50. Brenner AT, Ko LK, Janz N, Gupta S, Inadomi J (2015). Race/Ethnicity and Primary Language: Health Beliefs about Colorectal Cancer Screening in a Diverse, Low-Income Population. J Health Care Poor Underserved, 26(3), 824-38. (Read full article)
    51. Matsuzaki J, Suzuki H, Kobayakawa M, Inadomi JM, Takayama M, Makino K, Iwao Y, Sugino Y, Kanai T (2015). Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. PLoS One, 10(7), e0133865. (Read full article)
    52. Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG (2015). The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 24(7), 1012-23. (Read full article)
    53. Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C (2015). Optimising colorectal cancer screening acceptance: a review. Gut, 64(7), 1158-77. (Read full article)
    54. Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J, Aldulaimi D, Ho KY, Odze R, Meltzer SJ, Quigley E, Gittens S, Watson P, Zaninotto G, Iyer PG, Alexandre L, Ang Y, Callaghan J, Harrison R, Singh R, Bhandari P, Bisschops R, Geramizadeh B, Kaye P, Krishnadath S, Fennerty MB, Manner H, Nason KS, Pech O, Konda V, Ragunath K, Rahman I, Romero Y, Sampliner R, Siersema PD, Tack J, Tham TC, Trudgill N, Weinberg DS, Wang J, Wang K, Wong JY, Attwood S, Malfertheiner P, MacDonald D, Barr H, Ferguson MK, Jankowski J, BOB CAT Consortium (2015). BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol, 110(5), 662-82; quiz 683. (Read full article)
    55. Elmunzer BJ, Singal AG, Sussman JB, Deshpande AR, Sussman DA, Conte ML, Dwamena BA, Rogers MA, Schoenfeld PS, Inadomi JM, Saini SD, Waljee AK (2014). Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc, 81(3), 700-709.e3. (Read full article)
    56. Inadomi JM (2014). Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best Pract Res Clin Gastroenterol, 29(1), 51-63. (Read full article)
    57. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW (2014). Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS, 29(1), 43-51. (Read full article)
    58. Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S (2014). Quality indicators for EGD. Am J Gastroenterol, 110(1), 60-71. (Read full article)
    59. Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S (2014). Quality indicators for EGD. Gastrointest Endosc, 81(1), 17-30. (Read full article)
    60. Singal AG, Gupta S, Lee J, Halm EA, Rutter CM, Corley D, Inadomi J (2015). Importance of determining indication for colonoscopy: implications for practice and policy original. Clin Gastroenterol Hepatol, 12(12), 1958-63.e1-3. (Read full article)
    61. Biggins SW, Gralla J, Dodge JL, Bambha KM, Tong S, Barn AE, Inadomi J, Terrault N, Rosen HR (2014). Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant, 14(11), 2588-94. (Read full article)
    62. Gupta S, Brenner AT, Ratanawongsa N, Inadomi JM (2014). Patient trust in physician influences colorectal cancer screening in low-income patients. Am J Prev Med, 47(4), 417-23. (Read full article)
    63. Suzuki H, Matsuzaki J, Masaoka T, Inadomi JM (2014). Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy. Neurogastroenterol Motil, 26(6), 764-71. (Read full article)
    64. Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG (2014). Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev, 23(6), 997-1006. (Read full article)
    65. Day LW, Siao D, Inadomi JM, Somsouk M (2014). Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis. Endoscopy, 46(5), 401-10. (Read full article)
    66. Somsouk M, Too K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R (2013). Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdom Imaging, 39(2), 251-6. (Read full article)
    67. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragons N, van Ballegooijen M, Inadomi JM (2013). Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol, 109(3), 336-43; quiz 335, 344. (Read full article)
    68. Dimagno MJ, Wamsteker EJ, Rizk RS, Spaete JP, Gupta S, Sahay T, Costanzo J, Inadomi JM, Napolitano LM, Hyzy RC, Desmond JS (2014). A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis. Am J Gastroenterol, 109(3), 306-15. (Read full article)
    69. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM (2013). Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut, 63(2), 230-5. (Read full article)
    70. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY (2013). Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol, 12(2), 239-45. (Read full article)
    71. Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi JM (2015). Gastric cancer in asian american populations: a neglected health disparity. Asian Pac J Cancer Prev, 15(24), 10565-71. (Read full article)
    72. Rubenstein JH, Morgenstern H, McConell D, Scheiman JM, Schoenfeld P, Appelman H, McMahon LF Jr, Kao JY, Metko V, Zhang M, Inadomi JM (2013). Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology, 145(6), 1237-44.e1-5. (Read full article)
    73. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB (2013). American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology, 145(6), 1464-78.e1-5. (Read full article)
    74. Inadomi JM, Weinberg DS (2014). How to recognize a good guideline. Gastroenterology, 145(6), 1179-81. (Read full article)
    75. Day LW, Bhuket T, Inadomi JM, Yee HF (2013). Diversity of endoscopy center operations and practice variation across California's safety-net hospital system: a statewide survey. BMC Res Notes, 6, 233. (Read full article)
    76. Wernli KJ, Inadomi JM (2013). Anesthesia for colonoscopy: too much of a good thing? JAMA Intern Med, 173(7), 556-8. (Read full article)
    77. Sultan S, Falck-Ytter Y, Inadomi JM (2013). The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol, 11(4), 329-32. (Read full article)
    78. Ho C, Kornfield R, Vittinghoff E, Inadomi J, Yee H, Somsouk M (2013). Late presentation of colorectal cancer in a vulnerable population. Am J Gastroenterol, 108(4), 466-70. (Read full article)
    79. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM (2013). Prediction of Barrett's esophagus among men. Am J Gastroenterol, 108(3), 353-62. (Read full article)
    80. Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ (2012). How to value technological innovation: a proposal for determining relative clinical value. Gastroenterology, 144(1), 5-8. (Read full article)
    81. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP (2012). Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl, 18(12), 1471-8. (Read full article)
    82. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM (2012). The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology, 143(3), 567-575. (Read full article)
    83. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, Muoz R, Lau C, Somsouk M, El-Nachef N, Hayward RA (2012). Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med, 172(7), 575-82. (Read full article)
    84. Matsuzaki J, Suzuki H, Asakura K, Fukushima Y, Inadomi JM, Takebayashi T, Hibi T (2012). Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil, 24(4), 325-e164. (Read full article)
    85. Fass R, Inadomi J, Han C, Mody R, ONeil J, Perez MC (2011). Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol, 10(3), 247-53. (Read full article)
    86. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS (2011). Adverse events after screening and follow-up colonoscopy. Cancer Causes Control, 23(2), 289-96. (Read full article)
    87. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M (2011). Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc, 74(4), 885-96. (Read full article)
    88. Rubenstein JH, Morgenstern H, Kellenberg J, Kalish T, Donovan J, Inadomi J, McConnell D, Stojanovska J, Schoenfeld P (2011). Validation of a new physical activity questionnaire for a sedentary population. Dig Dis Sci, 56(9), 2678-87. (Read full article)
    89. Day LW, Cello JP, Somsouk M, Inadomi JM (2011). Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test. Indian J Gastroenterol, 30(5), 209-16. (Read full article)
    90. Buxbaum JL, Biggins SW, Bagatelos KC, Inadomi JM, Ostroff JW (2011). Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP, 12(4), 377-83. (Read full article)
    91. Brown LM, Rogers SJ, Cello JP, Brasel KJ, Inadomi JM (2011). Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. J Am Coll Surg, 212(6), 1049-1060.e1-7. (Read full article)
    92. Zheng P, Kornfield R, Olmo C, Guy J, Inadomi J, Biggins SW (2011). Reduced effectiveness of standard recruitment for deceased organ donor registration: the need for population-specific recruitment materials. Dig Dis Sci, 56(5), 1535-41. (Read full article)
    93. Limoges-Gonzalez M, Mann NS, Al-Juburi A, Tseng D, Inadomi J, Rossaro L (2011). Comparisons of screening colonoscopy performed by a nurse practitioner and gastroenterologists: a single-center randomized controlled trial. Gastroenterol Nurs, 34(3), 210-6. (Read full article)
    94. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological Association (2011). American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology, 140(3), e18-52; quiz e13. (Read full article)
    95. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology, 140(3), 1084-91. (Read full article)
    96. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM (2010). Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol, 106(2), 254-60. (Read full article)
    97. Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW (2011). Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl, 17(2), 129-36. (Read full article)
    98. Sewell JL, Inadomi JM, Yee HF Jr (2010). Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci, 55(12), 3479-87. (Read full article)
    99. Inadomi JM, Gunnarsson CL, Rizzo JA, Fang H (2010). Projected increased growth rate of anesthesia professional-delivered sedation for colonoscopy and EGD in the United States: 2009 to 2015. Gastrointest Endosc, 72(3), 580-6. (Read full article)
    100. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2011). Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care, 16(9), e228-34. (Read full article)
    101. Inadomi J (2010). Issues Related to BID Dosing of PPIs. Gastroenterol Hepatol (N Y), 6(6), 369-70. (Read full article)
    102. Menees SB, Inadomi J, Elta G, Korsnes S, Punch M, Aldrich L (2010). Colorectal cancer screening compliance and contemplation in gynecology patients. J Womens Health (Larchmt), 19(5), 911-7. (Read full article)
    103. Sewell JL, Yee HF Jr, Inadomi JM (2009). Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis, 16(2), 204-7. (Read full article)
    104. Dassopoulos T, Inadomi JM, Lewis JD, Allen JI (2009). The development of clinical guidelines by the American Gastroenterological Association. Gastroenterology, 138(2), 417-8. (Read full article)
    105. Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, OBrien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos G (2009). Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc, 70(6), 1182-99. (Read full article)
    106. Biggins SW, Bambha K, Terrault N, Inadomi J, Roberts JP, Bass N (2009). Transplant tourism to China: the impact on domestic patient-care decisions. Clin Transplant, 23(6), 831-8. (Read full article)
    107. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW (2009). New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol, 7(11), 1236-40. (Read full article)
    108. Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM (2009). Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther, 30(7), 741-8. (Read full article)
    109. Sewell JL, Kushel MB, Inadomi JM, Yee HF Jr (2009). Non-English speakers attend gastroenterology clinic appointments at higher rates than English speakers in a vulnerable patient population. J Clin Gastroenterol, 43(7), 652-60. (Read full article)
    110. Suzuki H, Inadomi JM, Hibi T (2009). Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil, 21(7), 688-96. (Read full article)
    111. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ (2009). A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology, 136(7), 2101-2114.e1-6. (Read full article)
    112. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT (2009). National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology, 49(5 Suppl), S4-S12. (Read full article)
    113. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, American College of Gastroenterology (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol, 104(3), 739-50. (Read full article)
    114. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009). Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol, 104 Suppl 2, S27-32. (Read full article)
    115. Inadomi JM (2009). Surveillance in Barrett's esophagus: a failed premise. Keio J Med, 58(1), 12-8. (Read full article)
    116. Inadomi JM (2009). Updates in colorectal cancer screening. F1000 Med Rep, 1. (Read full article)
    117. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT (2009). National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med, 150(2), 104-10. (Read full article)
    118. Inadomi JM (2009). Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence. J Gastroenterol Hepatol, 23 Suppl 2, S198-204. (Read full article)
    119. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi JM (2008). Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc, 68(5), 849-55. (Read full article)
    120. Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L (2008). Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol, 103(10), 2625-32; quiz 2633. (Read full article)
    121. Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, OBrien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Vieth M, Jass JR, Hurlstone PD (2008). Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc, 68(4 Suppl), S3-47. (Read full article)
    122. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM (2008). A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol, 103(6), 1358-64. (Read full article)
    123. Somsouk M, Gralnek IM, Inadomi JM (2008). Management of obscure occult gastrointestinal bleeding: a cost-minimization analysis. Clin Gastroenterol Hepatol, 6(6), 661-70. (Read full article)
    124. Somsouk M, Langfield DE, Inadomi JM, Yee HF Jr (2007). A cost-identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients. Dig Dis Sci, 53(4), 1093-9. (Read full article)
    125. Inadomi JM (2008). Fear of loss, not promise of gain, drives practice patterns in Barrett's esophagus. Gastroenterology, 134(4), 1258-60; discussion 1260. (Read full article)
    126. Inadomi JM, Somsouk MA (2007). Will virtual colonoscopy replace optical colonoscopy for colorectal cancer screening? Gastroenterology, 133(4), 1384-5; discussion 1385-6. (Read full article)
    127. Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Weinman B, Inadomi JM, Saad R, Chey WD (2007). Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther, 26(3), 443-52. (Read full article)
    128. Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorkowski JD Jr, AGA Institute (2007). AGA Institute review of endoscopic sedation. Gastroenterology, 133(2), 675-701. (Read full article)
    129. Elmunzer BJ, Inadomi JM, Elta GH (2007). Risk stratification in upper gastrointestinal bleeding. J Clin Gastroenterol, 41(6), 559-63. (Read full article)
    130. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, OHare AM (2007). Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med, 167(12), 1271-6. (Read full article)
    131. Inadomi JM, Somsouk MA (2007). Proton pump inhibitors and hip fracture: cause for alarm? Gastroenterology, 132(5), 2063-5; discussion 2065. (Read full article)
    132. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P (2006). On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol, 102(3), 642-53. (Read full article)
    133. Rubenstein JH, Inadomi JM, Brill JV, Eisen GM (2007). Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol, 5(3), 312-8. (Read full article)
    134. Vijan S, Hwang I, Inadomi J, Wong RK, Choi JR, Napierkowski J, Koff JM, Pickhardt PJ (2006). The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol, 102(2), 380-90. (Read full article)
    135. Inadomi JM (2007). Patients prefer conventional to virtual colonoscopy. Gastroenterology, 132(2), 809-11; discussion 811. (Read full article)
    136. Inadomi JM (2006). Implementing a research project: the nitty gritty. Gastrointest Endosc, 64(6 Suppl), S7-10. (Read full article)
    137. Heidelbaugh JJ, Inadomi JM (2006). Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol, 101(10), 2200-5. (Read full article)
    138. Rubenstein JH, Inadomi JM (2006). Evidence based medicine (EBM) in practice: applying results of cost-effectiveness analyses. Am J Gastroenterol, 101(6), 1169-71. (Read full article)
    139. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP (2006). Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 23(10), 1473-7. (Read full article)
    140. Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM (2006). Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Aliment Pharmacol Ther, 23(5), 655-68. (Read full article)
    141. Rubenstein JH, Inadomi JM (2006). Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol, 40(2), 109-15. (Read full article)
    142. Menees SB, Inadomi JM, Korsnes S, Elta GH (2005). Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointest Endosc, 62(2), 219-23. (Read full article)
    143. Rubenstein JH, Davis J, Marrero JA, Inadomi JM (2005). Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther, 22(3), 267-71. (Read full article)
    144. Rubenstein JH, Vakil N, Inadomi JM (2005). The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther, 22(2), 135-46. (Read full article)
    145. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW (2005). Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 100(6), 1237-42. (Read full article)
    146. Inadomi JM, Fendrick AM (2005). PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol, 3(3), 208-15. (Read full article)
    147. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P (2004). What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut, 53(12), 1736-44. (Read full article)
    148. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM (2004). Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther, 20(5), 507-15. (Read full article)
    149. Rubenstein JH, Eisen GM, Inadomi JM (2004). A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol, 99(7), 1274-88. (Read full article)
    150. Inadomi JM (2004). Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol, 16(6), 535-42. (Read full article)
    151. Inadomi JM, Fennerty MB, Bjorkman D (2003). Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther, 18(7), 671-82. (Read full article)
    152. Inadomi JM, McIntyre L, Bernard L, Fendrick AM (2003). Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol, 98(9), 1940-4. (Read full article)
    153. Inadomi JM, Sonnenberg A (2004). An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening. Clin Gastroenterol Hepatol, 1(5), 404-13. (Read full article)
    154. Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan S (2003). The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med, 163(13), 1601-5. (Read full article)
    155. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N (2003). Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med, 138(3), 176-86. (Read full article)
    156. Rhee J, Scheiman J, Inadomi J (2003). "Spontaneous" passage of a pancreatic duct stone. Gastrointest Endosc, 57(2), 278-80. (Read full article)
    157. Inadomi JM (2003). Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl, (237), 17-21. (Read full article)
    158. Inadomi JM (2005). Update on the cost-effectiveness of screening for colorectal neoplasia. Curr Opin Gastroenterol, 19(1), 44-50. (Read full article)
    159. El-Serag HB, Graham DY, Richardson P, Inadomi JM (2002). Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med, 162(18), 2105-10. (Read full article)
    160. Inadomi JM (2002). On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics, 20(9), 565-76. (Read full article)
    161. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg A (2001). Step-down management of gastroesophageal reflux disease. Gastroenterology, 121(5), 1095-100. (Read full article)
    162. Gorelick AB, Inadomi JM, Barnett JL (2001). Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol, 33(3), 210-4. (Read full article)
    163. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM (2001). Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol, 96(4), 979-83. (Read full article)
    164. Inadomi JM, Kapur S, Kinkhabwala M, Cello JP (2001). The laparoscopic evaluation of ascites. Gastrointest Endosc Clin N Am, 11(1), 79-91. (Read full article)
    165. Sonnenberg A, Delc F, Inadomi JM (2000). Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med, 133(8), 573-84. (Read full article)
    166. Inadomi JM, Sonnenberg A (2000). The impact of colorectal cancer screening on life expectancy. Gastrointest Endosc, 51(5), 517-23. (Read full article)
    167. El-Serag HB, Inadomi JM, Kowdley KV (2000). Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med, 132(4), 261-9. (Read full article)
    168. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM (1999). Corpus gastritis is protective against reflux oesophagitis. Gut, 45(2), 181-5. (Read full article)
    169. Sonnenberg A, Inadomi JM, Becker LA (1999). Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 13(8), 1003-13. (Read full article)
    170. Sonnenberg A, Inadomi JM, Bauerfeind P (1999). Reliability block diagrams to model disease management. Med Decis Making, 19(2), 180-5. (Read full article)
    171. Sonnenberg A, Inadomi JM (1999). Reliability block diagrams to model the management of colorectal cancer. Dig Dis Sci, 44(2), 314-21. (Read full article)
    172. Sonnenberg A, Inadomi JM (1999). Economic perspectives in the management of Helicobacter pylori infections. Curr Top Microbiol Immunol, 241, 237-60. (Read full article)
    173. Inadomi JM, Sonnenberg A (1998). The impact of peptic ulcer disease and infection with Helicobacter pylori on life expectancy. Am J Gastroenterol, 93(8), 1286-90. (Read full article)
    174. Sonnenberg A, Inadomi JM (1998). Review article: Medical decision models of Helicobacter pylori therapy to prevent gastric cancer. Aliment Pharmacol Ther, 12 Suppl 1, 111-21. (Read full article)
    175. Inadomi J, Sonnenberg A (1997). Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology, 113(4), 1289-94. (Read full article)
    176. Inadomi J, Cello JP, Koch J (1996). Ultrasonographic determination of ascitic volume. Hepatology, 24(3), 549-51. (Read full article)
    177. Inadomi J, Koch J, Cello JP (1995). Long-term follow-up of endoscopic treatment for bleeding gastric and duodenal ulcers. Am J Gastroenterol, 90(7), 1065-8. (Read full article)
    178. Miegel RE, Walker PS, Nelson PC, Inadomi J, Needelman L, Maxine M (1986). A compliant interface for total knee arthroplasty. J Orthop Res, 4(4), 486-93. (Read full article)

    Conference Proceedings

    1. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S (2017). Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointest Endosc, United States, 86(1), 1-17.e3. (Read full article)
    2. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA (2012). Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, United States, 143(2), 336-46. (Read full article)
    3. Rimola A, Garca-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM (2000). Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol, Netherlands, 32(1), 142-53. (Read full article)


    1. Inadomi JM (2020). What's App with GERD? Gastroenterology, 158(5), 1211-1212. (Read full article)
    2. Bibbins-Domingo K, Inadomi J (2018). Why "More Research Is Needed," Despite Overall Certainty: Women and Colorectal Cancer Screening. Ann Intern Med, 168(11), 824-825. (Read full article)
    3. Rutter CM, Inadomi JM (2017). Follow-up of Positive Fecal Test Results: Sooner Is Better, but How Much Better? JAMA, 317(16), 1627-1628. (Read full article)
    4. Friedman LS, Inadomi JM, Kalloo AM, Katzka DA, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR (2016). Introduction of Clinical Practice Update Committee Articles. Clin Gastroenterol Hepatol, 15(1), 4. (Read full article)
    5. Inadomi JM (2016). Colorectal Cancer Screening: Which Test Is Best? JAMA Oncol, 2(8), 1001-3. (Read full article)
    6. Inadomi JM (2012). Is 325 mg of prevention worth a pound of cure? Gastroenterology, 143(4), 885-7. (Read full article)
    7. Inadomi JM (2012). Why you should care about screening flexible sigmoidoscopy. N Engl J Med, 366(25), 2421-2. (Read full article)
    8. Inadomi JM (2011). Time to burn? Endoscopic ablation for Barrett's esophagus. Gastroenterology, 141(2), 417-9. (Read full article)
    9. Inadomi J (2010). Editorial: Interval cancers after colonoscopy: the importance of training. Am J Gastroenterol, 105(12), 2597-8. (Read full article)
    10. Inadomi JM (2008). In search of quality colonoscopy. Gastroenterology, 135(6), 1845-7. (Read full article)
    11. Inadomi JM, Terdiman J (2006). Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol, 4(8), 976-8. (Read full article)
    12. Rubenstein JH, Inadomi JM (2005). Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies. Gastrointest Endosc, 61(7), 809-11. (Read full article)
    13. Rubenstein JH, Inadomi JM (2003). Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable? Hepatology, 37(2), 249-52. (Read full article)


    1. Rutter CM, Inadomi JM (2017). Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test-Reply. [Letter to the editor]. JAMA, 318(5), 483-484. (Read full article)
    2. Inadomi JM (2017). Screening for Colorectal Neoplasia. [Letter to the editor]. N Engl J Med, 376(16), 1599-1600. (Read full article)
    3. Wernli KJ, Brenner AT, Rutter CM, Inadomi JM (2016). Reply. [Letter to the editor]. Gastroenterology, 151(3), 564. (Read full article)
    4. Rubenstein JH, Inadomi JM (2009). Potential for lead-time and length-time biases in outcomes in esophageal adenocarcinoma. [Letter to the editor]. Am J Gastroenterol, 104(12), 3106-7; author reply 3107-8. (Read full article)


    1. Inadomi JM (2021). Should all patients be tested for SARS-CoV-2 before endoscopy? GI & Hepatology News.


    1. Chiba N, Gralnek IM, Moayyedi P, Provenzale D, Inadomi JM, Willan AR, Briggs AH, Kim WR (2004). A glossary of economic terms. Eur J Gastroenterol Hepatol (16(6), pp. 563-5). England. (Read full article)